バイエルのインスタグラム(bayerofficial) - 7月21日 17時14分

Hemophilia
Bayer has a long history of research and development in the area of hemophilia. Hemophilia is a genetic defect and is inherited recessively on the X chromosome, so it primarily affects men. These patients lack a protein that among others causes the blood to clot as part of the natural wound-healing process. In hemophilia A, which affects 80-85 percent of patients with hemophilia, it is the blood clotting factor VIII that is lacking. Severe hemophilia is characterized by spontaneous bleeding into joints, muscles and various organs, even if there are no external injuries. This bleeding can lead to permanent disability or even death at any age.
Blood coagulation is a complex process - and a specialty of Bayer's scientists. 25 years after the recombinant factor VIII molecule was first used for the treatment of patients with hemophilia A, the company's specialists are working to enhance treatment options for #hemophilia patients.
#research #medicine #science #education #meds #medic #medical #doctor #lifescience #betterlife #chemistry #biology #scientist #robotic #agameoftones #artofvisuals #makemoments #visualsoflife #shoot2kill #way2ill #justgoshoot #liveauthentic #thecreatorclass #peoplescreatives #letsgosomewhere #everydayeverywhere #illgrammers #chasinglight #createxplore

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する